Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
9 evidence topics · 8 sources
Tumor hyperinsulinism: insulin receptor over-activation as described by the manufacturer
Insulinoma: insulin secretion not suppressed during hypoglycemia
“By definition, in endogenous hyperinsulinism, the insulin secretion does not decrease to very low levels when plasma glucose concentrations decrease to hypoglycemic levels” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, in patients with insulinoma, plasma insulin, C-peptide, and proinsulin concentrations are inappropriately high in the setting of low fasting plasma glucose concentrations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: somatic genetic and epigenetic changes
“Despite a low tumor mutational burden, insulinomas are enriched for genetic mutations and copy number variants in epigenetic modifiers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The predominant recurring genetic variant in up to 30% of insulinomas is an activating T372R mutation in the Yin Yang 1 (YY1) gene, which is absent in nonfunctioning panNEN” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“YY1 is a transcriptional activator of the insulin gene. MEN1 mutations appear to be less common in insulinomas than nonfunctioning panNEN, but insulinomas do display loss of heterozygosity of the MEN1 region at chromosome 11q13.1 in 30% of cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Insulinomas are also associated with aberrant methylation patterns, including of the insulin promoter, where noncanonical transcription factors drive insulin expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aggressive (malignant) versus indolent insulinoma: pathologic and molecular features
“Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, expression of ARX and alpha-1-antitrypsin and decreased or absent immunohistochemical expression of insulin, PDX1 and GLP-1R. Moreover, aggressive insulinomas often harbor ATRX or DAXX mutations, the alternative lengthening of telomeres phenotype and chromosomal instability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Aggressive insulinomas have similarities to normal alpha-cells and non-functional pancreatic neuroendocrine tumors, while indolent insulinomas remain closely related to normal beta-cells.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant versus benign insulinoma: hormone concentrations and tumor size in a single-center cohort
Non-islet cell tumor hypoglycemia: tumor IGF-2 release with suppressed insulin, IGF-1, and growth hormone
“Tumors of mesenchymal and epithelial origin produce IGF-2, which activates pathways in the tumors. In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are the most common among many) release into the circulation enough IGF-2-related peptides to mimic the fasting hypoglycemia characteristic of patients with insulin-producing islet-cell tumors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Typically, the elevated IGF-2 levels are associated with suppressed plasma levels of insulin, IGF-1, and GH. Complicating the pathophysiology are the IGF binding proteins (IGFBPs) that can bind IGF-2 and IGF-1, modifying hormone metabolism and action.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: incompletely processed big IGF-2 and its bioavailability
“Post-translational modifications of prepro-IGF-2 occur in the Golgi apparatus, where an intermediate molecule comprising the mature IGF-2 domain combined with part of the E-domain is formed and secreted into circulation in small quantities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The expression of high levels of IGF-2 RNA in such tumors results from a loss of imprinting of parent alleles and abnormal activation of promoter regions of the IGF-2 gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This leads to the production of large quantities of prepro-IGF-2, which oversaturates the prohormone convertase enzyme responsible for converting prepro-IGF-2 to mature IGF-2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Binary complexes, being smaller, can more easily permeate capillary membranes, resulting in higher bioavailability of IGF-2 and a greater potential for hypoglycemic action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rise in IGF-1 levels suppresses growth hormone (GH) secretion by the pituitary gland, which in turn reduces the production of ALS and IGFBP-3 by the liver. This creates a vicious cycle that further favors the formation of binary complexes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: effects of IGF-2 on glucose uptake, hepatic glucose output, and glucagon
“IGF-2 produced by tumor cells binds to IRs in skeletal muscle cells, leading to increased glucose uptake.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the liver, IGF-2 suppresses gluconeogenesis, glycogenolysis, ketogenesis, and the activity of glucose-6-phosphatase, thereby blocking hepatic glucose release.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, IGF-2 binds to IGF-1 and IR receptors on pancreatic alpha cells, suppressing glucagon release and exacerbating hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IGF‐2 typically demonstrates weak affinity for insulin receptors under normal physiological conditions. However, abnormally elevated levels of IGF‐2 can result in sufficient stimulation of insulin receptors, potentially inducing a state of clinically significant hypoglycaemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote